Evidence map›Paper›PMID 29523800›Full record

ArticleScientific reports2018

Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease.

Lauren M Byrne, Filipe B Rodrigues, Eileanoir B Johnson, Enrico De Vita, Kaj Blennow, Rachael Scahill, Henrik Zetterberg, Amanda Heslegrave, Edward J Wild

Open access · goldAbstract readControlled Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 34 citations in OpenAlex.

  1. Observational
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Lauren M ByrneInstitute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.
Filipe B RodriguesInstitute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.
Eileanoir B JohnsonInstitute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.
Enrico De VitaInstitute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.
Kaj BlennowClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, S-431 80, Mölndal, Sweden.
Rachael ScahillInstitute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.
Henrik ZetterbergInstitute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.
Amanda HeslegraveInstitute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK.
Edward J WildInstitute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK. e.wild@ucl.ac.uk.ORCID 0000-0002-6921-7887
National Hospital for Neurology and Neurosurgery · GBSahlgrenska University Hospital · SEQueen Mary University of London · GB

Funding

Medical Research Council MR/M008592/1
6 · The paper itself

Abstract

Biomarkers of Huntington's disease (HD) in cerebrospinal fluid (CSF) could be of value in elucidating the biology of this genetic neurodegenerative disease, as well as in the development of novel therapeutics. Deranged synaptic and immune function have been reported in HD, and concentrations of the synaptic protein neurogranin and the microglial protein TREM2 are increased in other neurodegenerative diseases. We therefore used ELISAs to quantify neurogranin and TREM2 in CSF samples from HD mutation carriers and controls. CSF neurogranin concentration was not significantly altered in HD compared to controls, nor was it significantly associated with disease burden score, total functional capacity or motor score. An apparent increase in CSF TREM2 in manifest HD was determined to be due to increasing TREM2 with age. After age adjustment, there was no significant alteration of TREM2 in either HD group, nor any association with motor, functional or cognitive score, or brain volume quantified by MRI. Both analyses were well-powered, and sample size calculations indicated that several thousand samples per group would be needed to prove that disease-associated alterations do in fact exist. We conclude that neither neurogranin nor TREM2 is a useful biofluid biomarker for disease processes in Huntington's disease.

Indexed as

AdultBiomarkersBrainCognitionFemaleHumansHuntington DiseaseMaleMembrane GlycoproteinsMiddle AgedMotor SkillsNeurograninReceptors, ImmunologicBiomarkersMembrane GlycoproteinsNeurograninReceptors, ImmunologicTREM2 protein, human

Identifiers

PMID29523800
PMCPMC5844906
OpenAlexW2788557010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.